MGC Pharmaceuticals Limited Update - Application for Admission to Trading

RNS Number : 6511D

MGC Pharmaceuticals Limited

19 February 2024

 

 

MGC Pharmaceuticals Ltd

Update - Application for Admission to Trading

19 February 2024

ASX, LSE: MXC

MGC Pharmaceuticals Ltd ("MGC Pharma" or the "Company") refers to its announcement entitled "Application for Admission to Trading" which was released on 13 February 2024. The Company wishes to advise that the application to admit 283,150 fully paid ordinary shares ("Admission Shares") to the Financial Conduct Authority's Official List and to trading on the Main Market of London Stock Exchange plc ("Admission") has been delayed. The Admission Shares, having already been admitted to trading on the Australian Stock Exchange ("ASX"), will not be affected by the delay and will continue to be tradable on the ASX. The total number of shares in issue and voting rights, being 43,851,631, remain unchanged. The Company will provide a further update on the Admission in due course.

-Ends-

 

Authorised for release by the Managing Director, for further information please contact:

MGC Pharmaceuticals Ltd      Roby Zomer CEO & Managing Director [phone] [e-mail]	MGC Pharmaceuticals Ltd Rowan Harland Company Secretary [phone] [e-mail]
UK IR/PR Advisers  IFC Advisory Graham Herring / Tim Metcalfe / Zach Cohen [phone] [e-mail]	UK Brokers Oberon Capital Aimee McCusker / Adam Pollock [phone] [e-mail] [e-mail]

 

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a prominent European pharmaceutical company with a strong commitment to creating accessible and ethically produced cutting-edge medicines. Our approach combines in-house research with innovative technologies, all aimed at discovering and producing treatments for currently unmet medical conditions.

 

The company's founders and executives are distinguished figures in the global pharmaceutical industry. Our central business strategy revolves around the development and supply of innovative medicines, responding to the increasing demand in the medical markets of Europe, North America, and Australasia.

 

MGC Pharma maintains a robust development pipeline that addresses two prevalent medical conditions, with additional products currently in the developmental stages. We've established strategic partnerships with renowned institutions and academia, fostering the optimization of our medicines' development. These medicines are produced in our EU-GMP Certified manufacturing facilities, ensuring the highest quality standards.

 

With a growing patient base in key regions like the USA, UK, Australia, and Ireland, MGC Pharma has also built a global distribution network through a wide-reaching group of commercial partners. This extensive network places us in a prime position to supply the global market effectively.

 

Follow us through our social media channels:

 

LinkedIn: MGC Pharmaceuticals Ltd.

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

Instagram: @mgc_pharma

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

FURFLFSVFVIALIS